Write in a clean editor, then format for Journal of Onco-Nephrology in one click — DocuGuru applies the official SAGE template with author–year references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
Journal of Onco-Nephrology is a peer-reviewed journal published by SAGE, covering Renal cell carcinoma treatment, Renal Diseases and Glomerulopathies, Amyloidosis: Diagnosis, Treatment, Outcomes.
| Publisher | SAGE |
|---|---|
| Reference style | Author–year (Harvard) Author–year — (Smith, 2023) in the text Smith, A., Jones, B. and Lee, C. (2023) 'A representative article title', Journal of Onco-Nephrology, 12(3), pp. 45–58.
Formats any DOI in Journal of Onco-Nephrology style. No sign-up. |
| Publishes research in | Renal cell carcinoma treatment Renal Diseases and Glomerulopathies Amyloidosis: Diagnosis, Treatment, Outcomes Chronic Lymphocytic Leukemia Research Cancer Immunotherapy and Biomarkers |
| ISSN | 2399-3693 |
| Citation impact (2-yr) | 0.32 |
| h-index | 11 |
| i10-index | 20 |
| Total citations | 595 |
| Top institutions publishing here | Yale University |
| Journal website | us.sagepub.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
The use of immune checkpoint inhibitors (ICI) in several cancers is expanding; however, their use in patients with cancer and an organ transplant is very limited. In this review, we summarize the literature and the experience of anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and anti-programmed cell death protein 1 (PD-1) inhibitors in the organ transplant patient.…
Cancer patients frequently suffer electrolyte abnormalities that complicate the management of their condition. The most commonly occurring derangement is hyponatremia, while hypercalcemia, hypokalemia, and hypophosphatemia are also encountered. The etiology of these abnormalities is often identifiable, and early diagnosis and management can prevent delays in necessary anti-cancer therapies.
Renal dysfunction because of radiation exposure was recognized decades ago. The incidence declined when more effective chemotherapeutic agents became available. However, there appears to be a resurgence with the advent of total body irradiation used prior to hematopoietic stem cell transplantation. Several chemotherapeutic drugs used prior to total body irradiation have some ionizing radiation potentiating…
The combination of endocrine therapy and cyclin-dependent kinase (CDK) 4/6 inhibitors is currently one of the preferred first-line regimens for patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. CDK 4/6 inhibitors can cause serum creatinine (SCr) elevation and corresponding estimated glomerular filtration rate (eGFR) reduction without…
Hyponatremia is the most common electrolyte disorder in patients with cancer and is associated with significant morbidity and mortality. Innovation in cancer therapies has led to substantial improvement in cancer outcomes, but also to new therapy-related toxicities, including electrolyte disturbance. Improvement in clinicians understanding of hyponatremia may mitigate adverse outcomes and improve quality of life…
